The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study.

Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Oct 2011Cited by 132 (Europe PMC)

PMID21773992DOI10.1002/jbmr.470PepBankPUB-21773992

Source link PubMedAsk about this study

Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with hypoparathyroidism, PTH(1-84) reduced daily calcium dose by 75% versus placebo.
In plain wordsIn patients with hypoparathyroidism, PTH reduced calcium supplement doses by 75% versus placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseCalcium supplement dose
Study
n = 62
Comparator
Placebo
Outcome group
Supplement requirements · Endocrine and hormones
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Measurements
Reduction in daily calcium dose
75%
PTH(1-84) versus placebo
Source sentences
Summary
Compared with placebo, patients on PTH(1-84) reduced their daily dose of calcium and active vitamin D significantly by 75% and 73%, respectively, without developing hypocalcemia.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399201
02HumanRandomized controlled trialEfficacy outcome
In patients with hypoparathyroidism, PTH(1-84) reduced daily active vitamin D dose by 73% versus placebo.
In plain wordsIn patients with hypoparathyroidism, PTH reduced active vitamin D doses by 73% versus placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseActive vitamin D dose
Study
n = 62
Comparator
Placebo
Outcome group
Supplement requirements · Endocrine and hormones
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Measurements
Reduction in daily active vitamin D dose
73%
PTH(1-84) versus placebo
Source sentences
Summary
Compared with placebo, patients on PTH(1-84) reduced their daily dose of calcium and active vitamin D significantly by 75% and 73%, respectively, without developing hypocalcemia.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399202
03HumanRandomized controlled trialEfficacy outcome
In patients with hypoparathyroidism, PTH(1-84) increased bone-specific alkaline phosphatase by 226% ± 36% versus placebo.
In plain wordsIn patients with hypoparathyroidism, PTH increased bone-specific alkaline phosphatase versus placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseBone-specific alkaline phosphatase
Study
n = 62
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Measurements
Increase in bone-specific alkaline phosphatase
226%
PTH(1-84) versus placebo; reported with ± 36% (spread type not stated)
Source sentences
Summary
Compared with placebo, PTH(1-84) treatment significantly increased plasma levels of bone-specific alkaline phosphatase (+226% ± 36%)
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399208
04HumanRandomized controlled trialEfficacy outcome
In patients with hypoparathyroidism, PTH(1-84) increased osteocalcin by 807% ± 186% versus placebo.
In plain wordsIn patients with hypoparathyroidism, PTH increased osteocalcin versus placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseOsteocalcin
Study
n = 62
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Measurements
Increase in osteocalcin
807%
PTH(1-84) versus placebo; reported with ± 186% (spread type not stated)
Source sentences
Summary
Compared with placebo, PTH(1-84) treatment significantly increased plasma levels of bone-specific alkaline phosphatase (+226% ± 36%), osteocalcin (+807% ± 186%)
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399209
05HumanRandomized controlled trialEfficacy outcome
In patients with hypoparathyroidism, PTH(1-84) increased P1NP by 1315% ± 330% versus placebo.
In plain wordsIn patients with hypoparathyroidism, PTH increased P1NP versus placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseP1NP
Study
n = 62
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Measurements
Increase in P1NP
1315%
PTH(1-84) versus placebo; reported with ± 330% (spread type not stated)
Source sentences
Summary
N-terminal propeptide of procollagen 1 (P1NP; +1315% ± 330%)
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with placebo, PTH(1-84) treatment significantly increased
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399210
06HumanRandomized controlled trialEfficacy outcome
In patients with hypoparathyroidism, PTH(1-84) increased CTX by 1209% ± 459% versus placebo.
In plain wordsIn patients with hypoparathyroidism, PTH increased CTX versus placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseCTX
Study
n = 62
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Measurements
Increase in CTX
1209%
PTH(1-84) versus placebo; reported with ± 459% (spread type not stated)
Source sentences
Summary
cross-linked C-telopeptide of type 1 collagen (CTX; +1209% ± 459%)
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with placebo, PTH(1-84) treatment significantly increased
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399211
07HumanRandomized controlled trialEfficacy outcome
In patients with hypoparathyroidism, PTH(1-84) increased urinary NTX by 830% ± 165% versus placebo.
In plain wordsIn patients with hypoparathyroidism, PTH increased urinary NTX versus placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseUrinary NTX
Study
n = 62
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Measurements
Increase in urinary NTX
830%
PTH(1-84) versus placebo; reported with ± 165% (spread type not stated)
Source sentences
Summary
and urinary cross-linked N-telopeptide of type 1 collagen (NTX; (+830% ± 165%)
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with placebo, PTH(1-84) treatment significantly increased
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399212
08HumanRandomized controlled trialEfficacy outcome
In patients with hypoparathyroidism, PTH(1-84) decreased hip BMD by 1.59% ± 0.57% versus placebo.
In plain wordsIn patients with hypoparathyroidism, PTH decreased hip bone density versus placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseHip BMD
Study
n = 62
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Measurements
Change in hip BMD
−1.59%
PTH(1-84) versus placebo; reported with ± 0.57% (spread type not stated)
Source sentences
Summary
whereas BMD decreased at the hip (-1.59% ± 0.57%), lumbar spine (-1.76% ± 1.03%), and whole body (-1.26% ± 0.49%) but not at the forearm.
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with placebo, PTH(1-84) treatment significantly increased
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399213
09HumanRandomized controlled trialEfficacy outcome
In patients with hypoparathyroidism, PTH(1-84) decreased lumbar spine BMD by 1.76% ± 1.03% versus placebo.
In plain wordsIn patients with hypoparathyroidism, PTH decreased spine bone density versus placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseLumbar spine BMD
Study
n = 62
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Measurements
Change in lumbar spine BMD
−1.76%
PTH(1-84) versus placebo; reported with ± 1.03% (spread type not stated)
Source sentences
Summary
whereas BMD decreased at the hip (-1.59% ± 0.57%), lumbar spine (-1.76% ± 1.03%), and whole body (-1.26% ± 0.49%) but not at the forearm.
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with placebo, PTH(1-84) treatment significantly increased
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399214
10HumanRandomized controlled trialEfficacy outcome
In patients with hypoparathyroidism, PTH(1-84) decreased whole body BMD by 1.26% ± 0.49% versus placebo.
In plain wordsIn patients with hypoparathyroidism, PTH decreased whole body bone density versus placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
DecreaseWhole body BMD
Study
n = 62
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Measurements
Change in whole body BMD
−1.26%
PTH(1-84) versus placebo; reported with ± 0.49% (spread type not stated)
Source sentences
Summary
whereas BMD decreased at the hip (-1.59% ± 0.57%), lumbar spine (-1.76% ± 1.03%), and whole body (-1.26% ± 0.49%) but not at the forearm.
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with placebo, PTH(1-84) treatment significantly increased
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399215
11HumanRandomized controlled trialEfficacy outcome
In patients with hypoparathyroidism, PTH(1-84) did not decrease forearm BMD versus placebo.
In plain wordsIn patients with hypoparathyroidism, PTH did not decrease forearm bone density versus placebo.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeForearm BMD
Study
n = 62
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Source sentences
Summary
whereas BMD decreased at the hip (-1.59% ± 0.57%), lumbar spine (-1.76% ± 1.03%), and whole body (-1.26% ± 0.49%) but not at the forearm.
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with placebo, PTH(1-84) treatment significantly increased
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399216
12HumanNon-randomized trialSafety outcome
Patients receiving PTH(1-84) reduced supplements without developing hypocalcemia.
In plain wordsPatients receiving PTH reduced supplements without developing low blood calcium.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
Not applicableHypocalcemia
Study
n: not reported in source
Outcome group
Adverse events · Endocrine and hormones
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, patients on PTH(1-84) reduced their daily dose of calcium and active vitamin D significantly by 75% and 73%, respectively, without developing hypocalcemia.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399203
13HumanNon-randomized trialSafety outcome
In patients receiving PTH(1-84), hypercalcemia occurred frequently during calcium and active vitamin D downtitration.
In plain wordsIn patients receiving PTH, high blood calcium occurred frequently during supplement dose reduction.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
Not applicableHypercalcemia
Study
n: not reported in source
Outcome group
Adverse events · Endocrine and hormones
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Source sentences
Summary
However, hypercalcemia occurred frequently during the downtitration of calcium and active vitamin D.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399204
14HumanNon-randomized trialEfficacy outcome
In patients with hypoparathyroidism, plasma phosphate did not change during PTH(1-84) treatment.
In plain wordsIn patients with hypoparathyroidism, blood phosphate did not change during PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changePlasma phosphate
Study
n: not reported in source
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Plasma phosphate and renal calcium and phosphate excretion did not change.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399205
15HumanNon-randomized trialEfficacy outcome
In patients with hypoparathyroidism, renal calcium excretion did not change during PTH(1-84) treatment.
In plain wordsIn patients with hypoparathyroidism, urinary calcium did not change during PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeRenal calcium excretion
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Plasma phosphate and renal calcium and phosphate excretion did not change.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399206
16HumanNon-randomized trialEfficacy outcome
In patients with hypoparathyroidism, renal phosphate excretion did not change during PTH(1-84) treatment.
In plain wordsIn patients with hypoparathyroidism, urinary phosphate did not change during PTH treatment.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeRenal phosphate excretion
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 µg daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Plasma phosphate and renal calcium and phosphate excretion did not change.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1-84) 100 µg or similar placebo for 24 weeks as add-on therapy to conventional treatment.
Report a problemFND-2177399207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.